banner-img

Live in the positive

VYLOY is a targeted treatment used in combination with chemotherapy as a first therapy for people with advanced* cancer of the stomach or the area where the esophagus joins the stomach (GEJ) that is HER2-negative and claudin 18.2 positive

+ CONNECTIONS   + POSSIBILITIES   + MOMENTS

+CONNECTIONS +POSSIBILITIES +MOMENTS

*Cancer that cannot be removed with surgery or has spread to other parts of the body.

GEJ=gastroesophageal junction.

VYLOY (zolbetuximab-clzb) is the first FDA-approved treatment that targets the biomarker claudin 18.2 in advanced stomach/GEJ cancer.

Learn about how and when VYLOY is given

Financial assistance and support is available for patients taking VYLOY